Navesta opens LKR1.4bn sterile drug plant in Sri Lanka

By Gareth Macdonald

- Last updated on GMT


Related tags Sri lanka

Navesta Pharmaceuticals had opened a sterile drug manufacturing facility in Horana, Sri Lanka.

The plant – which is compliant with European Union Good Manufacturing Practices (EU-GMP) and Pharmaceutical Inspection Co-Operation Scheme (PIC/S) standards - will make penicillin-based antibiotics for the local market.

According to Navesta the facility will initially manufacture 50 million vials per year. The firm said it plans to increase production capacity three-fold in the next few years.

Company chairman Sanjaya Jayaratne said: “Navesta’s ultimate aim is to provide a reliable, vertically integrated local supply chain which will provide accessibility of high quality pharmaceuticals for our citizens.”

In 2015​, the Sri Lankan Government introduced laws designed to encourage drug production in the country.

Navesta said the regulations had prompted it to invest LKR1.4bn ($9.1m) in construction and development of the facility

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Follow us